IMMUNOGENICITY OF DNA VACCINE CONSTRUCTS ENCODING INFLUENZA VIRUS ARTIFICIAL ANTIGENS

Cover Page


Cite item

Full Text

Abstract

Development of a universal influenza vaccine is an important task. One of approaches for develop a universal influenza vaccine is design of artificial immunogens, which consist of fragments from proteins of diff erent subtypes of influenza virus. Candidate universal DNA-vaccine were design in the FBSI SRC VB «Vector» earlier. The vaccine encode artificial antigens designed on the basis of conservative fragments of the hemagglutinin stem from influenza A virus of two subtypes H1N1 and H3N2, and on the basis of conservative protein M2. The article presents results of a study of the T-cell immune response in mice that were immunized with DNA-vaccine constructs encoding the designed influenza virus antigens.

About the authors

E. V. Starostina

State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor

Author for correspondence.
Email: starostina_ev@vector.nsc.ru

researcher of Bioengineering Department,

Koltsovo, Novosibirsk region

Russian Federation

O. N. Kaplina

State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor

Email: fake@neicon.ru

researcher of Bioengineering Department,

Koltsovo, Novosibirsk region

Russian Federation

L. I. Karpenko

State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor

Email: fake@neicon.ru

PhD, Dr. Sci., head of Recombinant vaccines Laboratory of Bioengineering Department,

Koltsovo, Novosibirsk region

Russian Federation

S. G. Dudko

State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor

Email: fake@neicon.ru

researcher of Bioengineering Department, 

Koltsovo, Novosibirsk region

Russian Federation

S. I. Bazhan

State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor

Email: fake@neicon.ru

PhD, Dr. Sci., head of Theoretical Department,

Koltsovo, Novosibirsk region

Russian Federation

References

  1. Wacheck V., Egorov A., Groiss F., Pfeiff er A., Fuereder T., Hoefl mayer D., Kundi M., Popow-Kraupp T., Redlberger-Fritz M., Mueller C.A., Cinatl J., Michaelis M., Geiler J., Bergmann M., Romanova J., Roethl E., Morokutti A., Wolschek M., Ferko B., Seipelt J., DickGudenus R., Muster T. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis. 2010, 1; 201(3), 354–62.
  2. López-Macías C. Virus-like particle (VLP)-based vaccines for pandemic infl uenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vaccin Immunother. 2012, 8(3), 411–4.
  3. Draper S. J., Cottingham M. G., Gilbert S. C. Utilizing poxviral vectored vaccines for antibody inductionprogress and prospects. Vaccine 2013, 31, 4223–30. 4. Vemula S. V., Ahi Y. S., Swaim A. M., Katz J. M., Donis R., Sambhara S., Mittal S. K. Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS One 2013, 8, 624–96.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Starostina E.V., Kaplina O.N., Karpenko L.I., Dudko S.G., Bazhan S.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies